Skip to main content

peramivir

Generic: PERAMIVIR·Brand: RAPIVAB, Rapivab

peramivir: 2 clinical trials tracked.

peramivir evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about peramivir, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA

NCT00486980Registry updated 2026-06-01·Phase 3·BCRX
Withdrawn
InterventionalRandomizeddouble0 enrolledBioCryst Pharmaceuticals

A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795Registry updated 2026-06-10·Phase 3·BCRX
Withdrawn

Primary endpoint: To evaluate the efficacy of peramivir administered intravenously compared to placebo on the time to alleviation of clinical symptoms with acute uncomplicated influenza.

InterventionalRandomizedquadruple0 enrolledStarted 2010-10Completion 2010-1150 sites · United StatesBioCryst Pharmaceuticals